论文部分内容阅读
应用美国ＣＨＩＲＯＮ公司ｋｅｒａｃｏｒ１１７型准分子激光治疗仪对６８例１３０眼近视患者行ＰＲＫ治疗。术前屈光度（等值球镜）为－２．００—－９．７５Ｄ（ｘ±ｓ：－５．１１±１．８１Ｄ）散光度０—－４．０Ｄ。结果：术后３—６个月残留屈光度为＋０．０８±０．２９Ｄ，裸眼视力≥０．８者占９４．２％，≥１．０者占９０．４％。术前屈光度－２Ｄ—－６Ｄ患眼，术后３—６个月裸眼视力≥０．８者占９５．２％，≥１．０者占９４．２％；术前屈光度－６．２５Ｄ—－９．７５Ｄ者，术后３—６个月裸眼视力≥０．８者占９１．７％，≥１．０占６５．４％。实际矫正度数在预测矫正度±０．５Ｄ范围内者占８４．６％，０．８％的术眼有２级以下的角膜上皮下雾状混浊，１．５％术眼角膜有丝状物，１．５％术眼用药后一过性眼压升高，最佳矫正视力下降１行者占５．２％。结论：ＰＲＫ治疗中低度近视是一种安全，有效的手术方法。其稳定性好，预测性强，值得临床应用。但术后应注意护理及随访。
Application of the United States CHIRON Keracor117 excimer laser treatment of 68 cases of 130 patients with myopia PRK treatment. Preoperative refraction (spherical equivalent) -2.00 - 9.75D (x ± s: -5.11 ± 1.81D) astigmatism 0--4.0D. Results: The residual refraction was +0.08 ± 0.29D in 3-6 months postoperatively, 94.2% in uncorrected visual acuity ≥0.8 and 90.4% ≥1.0. Preoperative diopter -2D - 6D eyes, 3-6 months after the naked eye vision ≥ 0.8 accounted for 95.2%, ≥ 1.0 accounted for 94.2%; preoperative diopter -6.25D- -9.75D, postoperative 3-6 months naked eye vision ≥ 0.8 accounted for 91.7%, ≥ 1.0 accounted for 65.4%. The actual degree of correction in the range of ± 0.5D predictive correction accounted for 84.6%, 0.8% of the surgical eyes have 2 below the corneal epithelium under the haze, 1.5% corneal filaments , 1.5% ophthalmic medication transient intraocular pressure increased, the best corrected visual acuity decreased by 1 line accounted for 5.2%. Conclusion: PRK is a safe and effective surgical method for treating low and middle myopia. Its stability, predictability, it is worth clinical application. But after surgery should pay attention to care and follow-up.